EST Viatris (VTRS) doesn’t see FDA warning impacting current 2024 financial guidanceDon't Miss Our Christmas Offers:Discover the latest ...

Shield Therapeutics ( (GB:STX) ) has issued an announcement.

Shares of Viatris Inc. VTRS slumped 0.72% to $12.40 Tuesday, on what proved to be an all-around favorable trading session for ...

For pharmaceutical development, this means faster access to life-saving medicines, reduced production costs and a sustainable approach to synthesizing drug candidates. Related Stories ...

Viatris said on Monday it has received a warning letter from the U.S. Food and Drug Administration after an inspection at its oral finished dose manufacturing facility in Indore, India earlier this ...

Prodose Inc., which also does business as Spirit Pharmaceuticals LLC and is located at 2004-02 Orville Dr. N. in Ronkonkoma, plans to close the local operation on Feb. 24, laying off its total ...

Yunnan Baiyao Group Co. Ltd. A 0.55% ¥107B Tasly Pharmaceutical Group Co. Ltd. A 1.09% ¥21.97B Jiangsu Hengrui Medicine Co. Ltd. A-0.62% ¥293.66B Zhejiang Hisun Pharmaceutical Co. Ltd. A 0.36% ...

LabVantage Pharma is the only pre-configured and pre-validated pharmaceutical LIMS in the world. This greatly lowers the deployment cost (85%) and time (75%) compared to a traditional LIMS ...

Viatris Inc. (NASDAQ:VTRS) is a healthcare company that offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).

Viatris said on Monday the U.S. Food and Drug Administration had restricted the importation of 11 products made at its drug manufacturing facility in India after warning about violations of federal ...

Viatris said on Monday the U.S. Food and Drug Administration has restricted imports of 11 products made at the drugmaker's ...

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE ...